RecruitingNot Applicable

Germline Genetic Testing of the TP53 Gene

Italy1,940 participantsStarted 2026-01-29

Plain-language summary

This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO; * Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used; * Have provided written informed consent for participation in scientific research. Exclusion Criteria: * Absence of signed informed consent for participation in scientific research.

What they're measuring

Overall detection rate of Pathological Variants (PVs) in the TP53 gene.

Timeframe: Baseline

Trial details

NCT IDNCT07419893

SponsorEuropean Institute of Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

Contact for this trial

Mariarosaria Calvello, MD

+39 0294372651 mariarosaria.calvello@ieo.it

View on ClinicalTrials.gov More TP53 Gene Mutation trials